IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 336 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,116,000 | +27.2% | 663,944 | +15.0% | 0.01% | +33.3% |
Q2 2023 | $23,680,000 | +33.6% | 577,138 | +16.4% | 0.01% | +20.0% |
Q1 2023 | $17,725,000 | -7.4% | 495,957 | -2.1% | 0.01% | 0.0% |
Q4 2022 | $19,145,000 | -0.9% | 506,845 | +16.0% | 0.01% | -16.7% |
Q3 2022 | $19,320,000 | +21.8% | 436,824 | +2.0% | 0.01% | +20.0% |
Q2 2022 | $15,861,000 | -3.7% | 428,423 | -3.6% | 0.01% | +25.0% |
Q1 2022 | $16,464,000 | +12.6% | 444,502 | -7.5% | 0.00% | +33.3% |
Q4 2021 | $14,626,000 | -10.9% | 480,648 | -1.8% | 0.00% | -25.0% |
Q3 2021 | $16,421,000 | -15.1% | 489,561 | +0.9% | 0.00% | -20.0% |
Q2 2021 | $19,346,000 | +169.6% | 484,966 | +203.8% | 0.01% | +150.0% |
Q1 2021 | $7,176,000 | -15.8% | 159,614 | +5.9% | 0.00% | 0.0% |
Q4 2020 | $8,519,000 | +16.2% | 150,687 | -2.5% | 0.00% | -33.3% |
Q3 2020 | $7,331,000 | -20.7% | 154,502 | -1.5% | 0.00% | -25.0% |
Q2 2020 | $9,247,000 | +21.8% | 156,830 | -2.4% | 0.00% | 0.0% |
Q1 2020 | $7,595,000 | -47.1% | 160,652 | -32.3% | 0.00% | -20.0% |
Q4 2019 | $14,346,000 | -3.8% | 237,471 | -4.6% | 0.01% | -16.7% |
Q3 2019 | $14,910,000 | -11.2% | 248,865 | -4.7% | 0.01% | -14.3% |
Q2 2019 | $16,789,000 | -10.7% | 261,222 | +12.8% | 0.01% | -12.5% |
Q1 2019 | $18,807,000 | +32.8% | 231,677 | -11.6% | 0.01% | +14.3% |
Q4 2018 | $14,159,000 | -46.0% | 261,936 | -48.5% | 0.01% | -36.4% |
Q3 2018 | $26,241,000 | +22.4% | 508,727 | -1.1% | 0.01% | +10.0% |
Q2 2018 | $21,439,000 | -19.7% | 514,516 | -15.1% | 0.01% | -16.7% |
Q1 2018 | $26,711,000 | +14.3% | 605,982 | +30.5% | 0.01% | +20.0% |
Q4 2017 | $23,367,000 | +112.7% | 464,525 | +114.4% | 0.01% | +100.0% |
Q3 2017 | $10,985,000 | -0.3% | 216,644 | -0.0% | 0.01% | -16.7% |
Q2 2017 | $11,023,000 | +186.5% | 216,710 | +126.4% | 0.01% | +200.0% |
Q1 2017 | $3,847,000 | -30.1% | 95,720 | -16.9% | 0.00% | -33.3% |
Q4 2016 | $5,507,000 | +12.2% | 115,136 | -14.1% | 0.00% | 0.0% |
Q3 2016 | $4,909,000 | +18.7% | 133,984 | -24.5% | 0.00% | +50.0% |
Q2 2016 | $4,135,000 | -45.7% | 177,575 | -5.5% | 0.00% | -50.0% |
Q1 2016 | $7,613,000 | -75.4% | 187,962 | -62.3% | 0.00% | -81.0% |
Q4 2015 | $30,905,000 | – | 499,021 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |